View All ZS Offices
Oncology Market Access at Risk: Is a Carrot for MDs a Stick for Pharma Companies
When Considering a Merger, Ask Why
Building the Fundamentals: Why Bold Sales Incentive Schemes Need Efficient Administration
Why Medtech's Commercial Models Must Adapt to Local Needs
Allergan Case Study: A Smart Response to Growth
Biopharma Companies Identify Biggest Challenges and Opportunities in Targeting and Activity Planning
Marie Yurkovich and Malik Kaman co-authored this blog post with Vikas Verma.
Antibodies that target immune checkpoints, like those against programmed cell death-1 (PD-1) or its ligand (PD-L1), have rapidly changed the oncology treatment landscape for multiple tumor types including melanoma, bladder cancer and non-small-cell lung cancer (NSCLC). Opdivo and Keytruda, the flagbearers for anti-PD-1 therapy, have collective sales of more than $8 billion alongside a presence in more than six oncology indications.
Read More